GSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk

Dow Jones

Apr 29

1039 GMT - GSK CEO Luke Miels says the U.K. pharmaceutical company's future deals could follow the pattern of its recent $2.2 billion acquisition of allergy-drug developer RAPT Therapeutics. The company could target companies working on drugs based on proven science that are developing products with an edge over those already on the market, Miels says in a call with reporters. In future dealmaking, GSK is more likely to focus on areas where it is already commercially active or those adjacent to them, as the barriers to expand into new fields are higher, he adds. GSK agreed to buy RAPT in January, just a few weeks after Miels took over as CEO, and closed the deal in March. Shares fall 2.5%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 29, 2026 06:39 ET (10:39 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2631592220"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2631592220\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2631592220?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 18:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631592220","market":"hk","top_or_hot":-1,"title":"GSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1039 GMT - GSK CEO Luke Miels says the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. pharmaceutical company's future deals could follow the pattern of its recent $2.2 billion acquisition of allergy-drug developer RAPT <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. The company could target companies working on drugs based on proven science that are developing products with an edge over those already on the market, Miels says in a call with reporters. In future dealmaking, GSK is more likely to focus on areas where it is already commercially active or those adjacent to them, as the barriers to expand into new fields are higher, he adds. GSK agreed to buy RAPT in January, just a few weeks after Miels took over as CEO, and closed the deal in March. Shares fall 2.5%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2026 06:39 ET (10:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-29 18:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1039 GMT - GSK CEO Luke Miels says the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. pharmaceutical company's future deals could follow the pattern of its recent $2.2 billion acquisition of allergy-drug developer RAPT <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. The company could target companies working on drugs based on proven science that are developing products with an edge over those already on the market, Miels says in a call with reporters. In future dealmaking, GSK is more likely to focus on areas where it is already commercially active or those adjacent to them, as the barriers to expand into new fields are higher, he adds. GSK agreed to buy RAPT in January, just a few weeks after Miels took over as CEO, and closed the deal in March. Shares fall 2.5%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2026 06:39 ET (10:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2631592220","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631592220","pubTimestamp":1777459140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1039 GMT - GSK CEO Luke Miels says the U.K. pharmaceutical company's future deals could follow the pattern of its recent $2.2 billion acquisition of allergy-drug developer RAPT Therapeutics. The company could target companies working on drugs based on proven science that are developing products with an edge over those already on the market, Miels says in a call with reporters. In future dealmaking, GSK is more likely to focus on areas where it is already commercially active or those adjacent to them, as the barriers to expand into new fields are higher, he adds. GSK agreed to buy RAPT in January, just a few weeks after Miels took over as CEO, and closed the deal in March. Shares fall 2.5%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU1829250122.USD":"高盛欧洲核心股票组合Acc","RAPT":"RAPT Therapeutics, Inc.","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","GSK.UK":"葛兰素史克","BK4007":"制药","GSKH":"GSK plc ADRhedged","GSK":"葛兰素史克","BK4588":"碎股"},"translate_title":"葛兰素史克首席执行官将RAPT Therapeutics收购视为未来交易的模板——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1.5,"GSK.UK":0.6,"RAPT":1.5,"GSKH":0.6},"content_text":"1039 GMT - GSK CEO Luke Miels says the U.K. pharmaceutical company's future deals could follow the pattern of its recent $2.2 billion acquisition of allergy-drug developer RAPT Therapeutics. The company could target companies working on drugs based on proven science that are developing products with an edge over those already on the market, Miels says in a call with reporters. In future dealmaking, GSK is more likely to focus on areas where it is already commercially active or those adjacent to them, as the barriers to expand into new fields are higher, he adds. GSK agreed to buy RAPT in January, just a few weeks after Miels took over as CEO, and closed the deal in March. Shares fall 2.5%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2026 06:39 ET (10:39 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}